Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 7:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2257–2280 of 3,500 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Protein Control Clear all

Conditions: Alzheimer´s Disease
Interventions: Immune Globulin Intravenous (Human), 10% Solution, Human albumin 0.25%; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 50 Years to 89 Years
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 34 more

Conditions: Arthritis, Rheumatoid
Interventions: TRU-015, Methylprednisolone, Prednisone; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 29
States / cities: Birmingham, Alabama • Paradise Valley, Arizona • Los Angeles, California + 24 more

Conditions: Lupus Nephritis, Lupus Erythematosus, Systemic
Interventions: abatacept, cyclophosphamide, azathioprine, prednisone, abatacept placebo, azathioprine placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 21
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 16 more

Conditions: Autism Spectrum Disorder, Gastro-Intestinal Disorder, Constipation, Diarrhea
Interventions: vancomycin, Miralax, intestinal microbiota, placebo vancomycin, Miralax, placebo intestinal microbiota; Combination Product
Lead sponsor: Arizona State University; Other
Eligibility: 5 Years to 17 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Recurrent Herpes Labialis
Interventions: Merlin, Ethanol; Drug
Lead sponsor: Topical Remedy; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more

Conditions: Female Reproductive Cancer
Interventions: serum-derived bovine immunoglobulin protein isolate, placebo, laboratory biomarker analysis, quality-of-life assessment, questionnaire administration; Biological · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Type 2 Diabetes Mellitus
Interventions: Not listed
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 40 Years and older
Enrollment: 874 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 15
States / cities: Phoenix, Arizona • Tucson, Arizona • Fresno, California + 12 more

Conditions: Von Willebrand Disease
Interventions: von Willebrand factor (Recombinant), Antihemophilic Factor (Recombinant); Biological
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 8
States / cities: Loveland, Colorado • Gainesville, Florida • Jacksonville, Florida + 5 more

Conditions: Diabetes Mellitus, Type 2, Renal Insufficiency
Interventions: Canagliflozin, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 25 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 26
States / cities: Concord, California • Fountain Valley, California • San Diego, California + 23 more

Conditions: Diabetes Mellitus, Type 2
Interventions: LY2189265, Exenatide, Placebo, Metformin, Pioglitazone; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 978 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 78
States / cities: Goodyear, Arizona • Phoenix, Arizona • Cathedral City, California + 75 more

Conditions: HIV Infections
Interventions: env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, GLA-SE adjuvant, Placebo; Biological
Lead sponsor: Worcester HIV Vaccine; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alopecia Areata
Interventions: Abatacept, placebo; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Leg Spasticity
Interventions: Botulinum toxin type A, Placebo; Biological · Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 388 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 17
States / cities: Scottsdale, Arizona • Downey, California • Oxnard, California + 12 more

Conditions: Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
Interventions: Pregabalin, Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 10
States / cities: Los Angeles, California • Stanford, California • Chicago, Illinois + 6 more

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: BG00012, Placebo, Glatiramer Acetate; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 72
States / cities: Birmingham, Alabama • Cullman, Alabama • Huntsville, Alabama + 69 more

Conditions: COVID-19
Interventions: Interferon beta-1a, Placebo, Remdesivir; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 969 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 55
States / cities: Birmingham, Alabama • Fresno, California • La Jolla, California + 45 more

Conditions: IO Resistant Squamous and Nonsquamous NSCLC
Interventions: TAK-928, Control Arm; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 12
States / cities: Jonesboro, Arkansas • Fair Oaks, California • Fountain Valley, California + 9 more

Conditions: Postmenopausal Osteoporosis
Interventions: Romozosumab, Teriparatide; Drug
Lead sponsor: Amgen; Industry
Eligibility: 55 Years to 90 Years · Female only
Enrollment: 436 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 5
States / cities: Gainesville, Georgia • Bethesda, Maryland • Boston, Massachusetts + 1 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Hydrolysed infant formula, Nonhydrolysed infant formula; Dietary Supplement
Lead sponsor: University of Helsinki; Other
Eligibility: Up to 7 Days
Enrollment: 5,156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2017
U.S. locations: 2
States / cities: Tampa, Florida • Pittsburgh, Pennsylvania

Conditions: Crohn's Disease
Interventions: abatacept, placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 37
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 33 more

Conditions: Chronic Tympanic Membrane Perforation
Interventions: Fibroblast Growth Factor 2, Saline control; Drug
Lead sponsor: D. Bradley Welling, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: C-reactive Protein, Inflammation, Obesity, Oxidative Stress
Interventions: Vitamin C (ascorbic acid), Placebo tablet; Dietary Supplement
Lead sponsor: University of California, Berkeley; Other
Eligibility: 18 Years and older
Enrollment: 512 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Oakland, California

Conditions: ASC-US, ASC-H, LSIL
Interventions: PVX-2, Placebo; Biological · Other
Lead sponsor: PapiVax Biotech, Inc.; Other
Eligibility: 25 Years to 70 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 6
States / cities: Port Saint Lucie, Florida • Newark, New Jersey • Fairfield, Ohio + 3 more

Conditions: HIV
Interventions: Atazanavir, Placebo; Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 45 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Phase 3 IGIV, 10% in Alzheimer´s Disease

Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis

Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis

MTT for Children With ASD Who Have Gastrointestinal Disorders

Safety and Efficacy of Merlin (Ethanol and Glycolic Acid Mixture) for Episodic Treatment of Cold Sores

Serum Bovine Immunoglobulin Protein Isolate in Improving Quality of Life and Post-Operative Recovery in Patients With Gynecological Cancer After Undergoing Surgery

Fatty Acid Binding Protein 2 (FABP2) Ancillary Proposal

rVWF IN PROPHYLAXIS

An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment

A Study in Participants With Type 2 Diabetes Mellitus

Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults

A Clinical Trial to Evaluate the Efficacy of Abatacept in Moderate to Severe Alopecia Areata

Dysport® Adult Lower Limb Spasticity Study

Efficacy & Safety Study of Pregabalin to Treat Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)

Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis

Adaptive COVID-19 Treatment Trial 3 (ACTT-3)

A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer

An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women

TRIGR - Primary Prevention Study for Type 1 Diabetes in Children at Risk

A Study of Abatacept in Patients With Active Crohn's Disease

In-office Repair of Chronic Tympanic Membrane Perforations

Obesity, Inflammation and Oxidative Stress

Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL

Atazanavir and Endothelial Function in Older HIV Patients